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Abstract: A main challenge in nutritional studies is the valid and reliable assessment of food intake,
as well as its effects on the body. Generally, food intake measurement is based on self-reported
dietary intake questionnaires, which have inherent limitations. They can be overcome by the use
of biomarkers, capable of objectively assessing food consumption without the bias of self-reported
dietary assessment. Another major goal is to determine the biological effects of foods and their impact
on health. Systems analysis of dynamic responses may help to identify biomarkers indicative of
intake and effects on the body at the same time, possibly in relation to individuals’ health/disease
states. Such biomarkers could be used to quantify intake and validate intake questionnaires, analyse
physiological or pathological responses to certain food components or diets, identify persons with
specific dietary deficiency, provide information on inter-individual variations or help to formulate
personalized dietary recommendations to achieve optimal health for particular phenotypes, currently
referred as “precision nutrition.” In this regard, holistic approaches using global analysis methods
(omics approaches), capable of gathering high amounts of data, appear to be very useful to identify
new biomarkers and to enhance our understanding of the role of food in health and disease.
Keywords: food intake assessment; integrative biomarkers; omics technologies; precision nutrition
1. Introduction
The nutritional status of an individual reflects the extent to which their physiological needs of
nutrients have been covered at a particular life stage. When the nutrients to support daily body
needs and metabolic demands are consumed in a balanced manner, without insufficiency or excess,
the person presents an optimal nutritional status that favours growth, development, appropriate
cell/tissue turnovers and global health.
Dietary assessment and nutritional status are traditionally measured by means of dietary intake
data, such as 24-h dietary recalls, food records or food frequency questionnaires [1]. Even though
recent technological advances, including image analysis software, to collect dietary information or
to process dietary data, have improved dietary assessment, food-intake based methods have some
inherent limitations, such as:
Subjective nature of data collection tools. People do not always remember everything they have
consumed or are not able to recall all foods eaten or their specific ingredients/components or they
may have difficulty estimating portion sizes accurately [2]. This combination of factors determines
measurement errors in dietary assessment. Moreover, individuals often underreport dietary intake,
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particularly when reporting intakes which have higher social desirability and, for those who have a
history of dieting and being overweight, reflect greater eating restraint [3,4].
Limitations of food composition tables. Some nutrients, such as the vast majority of trace elements,
are not sufficiently characterised in food composition tables and, therefore, nutritional status cannot be
assessed correctly based on intake [5]. This is also the case for certain fat-soluble vitamins. Fats and
oils constitute the main nutritional source of vitamin E; however, the content of this vitamin varies
depending on the type of oil, its processing, the addition of antioxidants and its shelf life, all of which
cannot be characterised in a dietary assessment. On the other hand, the nutritional content of food is
neither consistent nor uniform and food composition databases may not reflect the characteristics of
the products currently commercialised. They generally lag behind current eating patterns, for example,
the tendency for whole grain products is poorly reflected.
Factors influencing nutrient absorption. Certain nutrients have feedback control mechanisms
that increase or decrease the efficiency of absorption depending on nutritional status; for example,
an individual with a low nutritional calcium status will absorb calcium more efficiently [6]. Certain
food combinations can affect absorption; for example, the fibre content of a meal may decrease the
availability of food carotenoids [7], whereas the vitamin C content promote iron absorption when
ingested at the same time [8]. Vitamin D was shown to be better available from milk than from solid
food [9]. The extent of cooking of foods may also influence composition, including nutrient content and
absorption, such is the case of vitamin B6 and vitamin C [6]. Finally, the degree of processing may affect
absorption, since micronutrients can be associated with proteins that facilitate their bioavailability,
which has been shown, for example, for calcium [10] and zinc [11] or which are better available in their
native form (e.g., heme-iron, Fe3+) [12]. These factors are generally not considered, because dietary
questionnaires do not include enough detail on how food is prepared or processed and do not capture
information about foods eaten together.
2. Biomarkers of Nutritional Status
The limitation of dietary assessment to estimate nutritional status determines the need for analytical
determinants that can objectively and accurately quantify nutritional status. Biomarkers provide
a more proximal measure of nutrient status than dietary intake. Generally speaking, a nutritional
biomarker is a characteristic that can be objectively measured in different biological samples and
can be used as an indicator of nutritional status with respect to the intake or metabolism of dietary
constituents [6]. Examples of suggested nutritional biomarkers are shown in Table 1.
The biochemical analysis of a reference metabolite that indicates the bioavailability of a nutrient is
an objective result to assess nutritional status, which entails lower methodological error and detects
deficiency states more precisely than dietary assessment. Such biomarkers are generally based on
pronounced changes observed in one parameter. They are clinically useful, in particular to detect
deficiencies in support of medical treatment. Analysis of folate, iron and vitamin B12 but also copper
and zinc, is useful to identify potential nutritional causes of anaemia [13]. The development of
biomarkers faithfully representing the nutritional status for those micronutrients is clearly justified by
their usefulness in medicine.
Clinical biomarkers are focused on diagnosis of a disease state. In most cases these are independent
of nutrition but comprise the best parameter that reflects a certain disease. In case of metabolic diseases,
overlap may occur, for example, this is the case for circulating lipid profiles, urea levels in blood or urine
and so forth. In most instances, clinical diagnosis of disease differs from nutritional biology, that focuses
on health, that is, whether the nutritional status is such that it supports health or not. The latter
can also entail mild subclinical deficiencies as well as moderate excess. Especially in those cases,
the combination of both methodologies, dietary assessment by food questionnaires with biochemical
measures, can provide a useful tool for estimating the exposure to a particular nutrient of interest and
assessing health risks. This combination may eliminate some of the errors associated with each type
methods to assess nutritional status [6].
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Table 1. Examples of suggested nutritional biomarkers related with exposure and/or effects of
macronutrients, food or dietary patterns, in samples obtained with non-invasive or minimally invasive
techniques. Some representative references are provided for each candidate biomarker.
Proposed Biomarker Sample Type Intended Use(As Nutritional Biomarker) References
Alkylresorcinols Plasma Whole-grain food consumption Original research [14,15]Reviewed in Reference [16]
Allyl methyl sulfoxide (AMSO)
or allyl methyl sulfone (AMSO2)
Urine Intake of garlic Original research [17]BFIRev ** [18]
Allyl methyl sulphide (AMS) Urine/breath Intake of garlic Original research [17,19,20]BFIRev [18]
Arbutin Plasma Pear intake Original research [21]BFIRev [22]
Carotenoids Plasma Fruit and vegetable intake Systematic review andmeta-analysis [23]
Carotenoids with Vitamin C Plasma/serum
Fruit and vegetable intake
Combined marker (suggested as
better biomarker than carotenoids
or vitamin C alone)
Reviewed in Reference [24]
Creatine Serum Intake of meat and fish Reviewed in Reference [25]
Creatinine Urine Intake of meat and fish Reviewed in Reference [25]
Daidzein Urine/plasma Intake of soy or soy-based products Systematic review [26]
Dyhydrocaffeic acid derivatives Urine Acute and habitualexposure to coffee
Original research [27–29]
Reviewed in Reference [30]
Erythronic acid, alone or with
fructose and/or sucrose Urine
Sugar intake
Combined marker Original research [31]
Genistein Urine/plasma Intake of soy or soy-based products Systematic review [26]
Homocysteine Plasma One carbon metabolismand folate status Reviewed in References [32,33]
Hydroxylated and sulfonated
metabolites of esculeogenin B Urine Intake of tomato juice Original research [34]
1-Methylhistidine Urine Meat and oily fish consumption Original research [27,35,36]Reviewed in References [30,37]
n-3 fatty acids: docosahexaenoic
acid (DHA)
Blood: erythrocytes
or platelets DHA status Systematic review [38]
n-3 fatty acids: DHA
(as phospholipid) Plasma DHA status Systematic review [38]
n-3 fatty acids: eicosapentaenoic
acid (EPA as phospholipid) Plasma EPA status Systematic review [38]
N-acetyl-S-(2carboxypropyl)cysteine
(CPMA) Urine Intake of onion and garlic
Original research [39]
BFIRev [18]
Nitrogen* Urine (24h) Protein intake Reviewed in Reference [40]
O-acetylcarnitine Urine Red-meat consumption Original research [41]Reviewed in Reference [42]
Pentadecanoic acid (C15:0) Plasma/serum Total dairy fat intake Reviewed in Reference [43]
Phenylacetylglutamine Urine Vegetable intake Original research [41]Reviewed in Reference [30]
Phloretin Urine Apple intake Original research [44,45]BFIRev [22]
Phloretin glucuronide Urine Apple intake Original research [46,47]BFIRev [22]
Proline betaine Urine Acute and habitual citrus exposure Original research [27,48,49]Reviewed in Reference [30]
S-allylcysteine (SAC) Plasma Intake of garlic Original research [19]BFIRev [18]
S-allylmercapturic acid (ALMA) Urine Intake of garlic Original research [50]BFIRev [18]
Urolithin B Urine
Intake of ellagitannins (present in
fruits as strawberries, raspberries
and walnuts and oak-aged red wine,
among others)
Original research [51]
* Nitrogen in 24 h urine is an already substantially validated biomarker of protein intake. ** BFIRev: Biomarker
of Food Intake Review. This type of review follows specific recent guidelines for the review, identification and/or
validation of candidate biomarkers of food intake [52].
Nutrients 2019, 11, 1092 4 of 30
To understand the complex relationships between nutrition and health, different types of
biomarkers are being used in nutritional studies: markers of exposure, of effect (or function) and of
health/disease state [53].
Biomarkers of exposure. These include the different types of biomarkers used to evaluate dietary
intake of nutrients, non-nutritive food components or dietary patterns. An example is the nitrogen
in urine [40], which serves as a biomarker for protein intake. These types of biomarkers are of great
interest, as their use can help to improve the categorization of subjects according to the exposure to a
particular nutrient. They also serve as an objective indicator of compliance with a particular dietary
regimen in intervention studies investigating the health effects of dietary modifications [54]. These
biomarkers may not only reflect one nutrient but may also be associated with a dietary pattern or
food group, for example, the plasma concentration of alkylresorcinol is considered a biomarker of
the intake of whole grains [14] and the combination of sucrose or fructose with erythronic acid is a
urinary biomarker for sugar intake [31]. Urine/plasma genistein and daidzein are also biomarkers for
soy or soy-based product intake [26], while robust information for markers of other legumes is still
lacking. In this sense a combination of markers may better reflect a food category, for example vitamin
C and carotenoids together may be more accurate that either of these fruit and vegetable biomarkers
alone [24].
Biomarkers of effects. These are biomarkers that are related to a target function or biological
response. Thus, not only do they reflect intake but also nutrient metabolism and, possibly, effects on
physiological or disease processes. It is important to note that a biomarker may not reflect the effect of
a single nutrient but the interactions of various nutrients. For example, some of the biomarkers of the
metabolism of one carbon compounds such as homocysteine, which reflect not only nutritional intake
but also various metabolic processes related with pathological or physiological conditions [32,33].
Biomarkers of health/disease and physiological status. These are biomarkers which indicate
an end-point, relate to a state of health and/or disease risk. These markers reflect the different
intermediate disease phenotypes or the severity of the disease and are widely used in clinical practice.
For example, plasma levels of fasting glucose are associated with insulin sensitivity and diabetes
or plasma cholesterol and triglycerides are linked to cardiovascular disease. Nutritional biomarker
research is not focused on identification and characterization of diseases or treatment prognostics,
which are areas of intense development.
3. Current Challenges in the Development of Health Biomarkers
The development of health/disease biomarkers was driven by medical needs and has largely
been directed towards identifying and quantifying disease states or progression, rather than assessing
and quantifying the health status of an individual. However, the main objective of diet and nutrition
is to promote and maintain optimal health. Therefore, it is highly relevant to have biomarkers of
very early stages of alterations that may ultimately progress to disease, even before what may be
considered the onset of the disease. Such biomarkers can be considered health and/or prevention
markers rather than disease markers. Pre-disease physiological alterations are likely to be associated
with pre-disease alterations in homeostatic balance and may be identified when the homeostatic
response to a particular environmental or nutritional aggression is examined [55]. These biomarkers
represent a new approach to biomarkers that reflect maintenance of physiological integrity and function.
In this context, health-promoting food components support or even optimise, a healthy physiology,
preventing or delaying initiation of a disease state or a loss of physiological function, including
cognitive function. Because of the multifaceted nature of homeostasis, nutrigenomic technologies,
which analyse functional genomic responses on a genome-wide scale applied to the field of nutrition,
have been particularly valuable and will continue to be so, for the identification, characterisation and
validation of health biomarkers.
Human health is based on a complex network of interactions between pathways, processes and
molecules, implying interactive mechanisms and across different cells, tissues and organs. Various
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biochemical and physiological mechanisms are responsible for maintaining health in an environment
that is constantly changing, as a result of, for example, diet, infections, temperature, exercise and various
other stressors. In good health, the mechanisms that maintain homeostasis are able to effectively buffer
the different challenges that individuals are subjected to. The adaptation response defines the so-called
phenotypic flexibility [56]. The way to the disease starts when and where these adaptive processes and
regulatory networks fail. Lifestyle and other conditions, both environmental and internal, can reduce
the robustness and elasticity of these mechanisms. Then the homeostatic machinery becomes less
effective and produces negative side effects, which can occur from the molecular to the whole-body
level. An example is excessive accumulation of lipids in the liver, which can be a consequence of the
diminished capacity of adipose tissue for lipid storage [57]. This results in an organism that has lost its
ability to react adequately to external challenges, which further aggravates the situation, for example
by the development of insulin resistance. This loss of an adequate physiological performance, resulting
in the inability to maintain healthy responses, can be the basis for the development of new biomarkers,
reflecting dynamic responses, to assess health status and the capacity for its metabolic flexibility.
Biomarkers of health can guide policies related to food, nutrition and health. In fact, they would
represent the basis for the substantiation of health claims on food. At present, the lack of robust
nutritional biomarkers for many biological functions is a bottleneck that slows down innovation in
the food industry. This is recognized and taken up by the scientific community. One example is
BIOCLAIMS (FP7-244995), a collaborative research project carried out at the European level, which
has established the principles to identify, establish and validate robust biomarkers to quantify the
health status. Examining the influence of bioactive components of the diet on these biomarkers,
provides the basis for evidence-based development of foods with reliable health properties that can
contribute to a healthier diet and health in the long term. Other initiatives, such as PREVENTOMICS
(DT-SFS-14-2018-818318), a project funded by the European Union’s program Horizon 2020 under the
call ICT-04-2017—Personalized Nutrition, aims to use health biomarkers in dietary advice applications
for consumers.
The New Concept of Integrative Nutritional Biomarkers
In terms of nutrition, health biomarkers are the cornerstone of research that establishes the
functional effects of nutrition on the health-disease relationship. Currently, given the complex
relationship between food intake and health/disease status, a more integrative understanding of the
concept of biomarker in relation to nutritional status and health is being developed, by focusing in
nutritionally-regulated biomarkers of health. The concept is that intake is quantified, not only in
terms of what is eaten but also in terms of the evoked biological response. As an example, circulating
lipid profiles reflect intake but also depend on nutritional context, genotype and health status [58].
Similarly, a specific protein modification may be a physiological response that may also reflect intake.
The development of such a new type of biomarker with an integrative trait, integrative nutritional
biomarkers, recognizes the intimate connection between nutrition and metabolism. They could
be indicative of both intake and of effects on the body and could even reflect health/disease state.
Integrative nutritional biomarkers use the fact that nutrition and metabolism are intimately connected,
which is considered an advantage rather than a hindrance and source of variation. They may be
defined by a single parameter but more likely a set of directly connected parameters, for example a
protein and its physiology and nutrient induced modifications or a spectrum of plasma lipids but can
also consist of an integrating algorithm based on several parameters, each reflecting a particular aspect
of metabolism and nutrient exposure and availability. Such biomarkers could be analytical indicators,
which would be quantitative and acting as an intake (short- or long-term exposure) indicator and/or
pointing to the status of a particular nutrient or food component and integrate the impact of intake on
the body (effect). Integrative nutritional biomarkers could be used to quantify effective intakes and
validate or complement intake questionnaires, shed light on physiological or pathological responses
to certain food behaviours, monitor responses to therapeutic interventions that could be optimised
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and more personalised and provide information on inter-individual variations in response to the diet.
Furthermore, they may help to formulate personalized dietary recommendations to achieve optimal
health and wellness for particular phenotypes and genotypes, currently referred to as “precision
nutrition” [59]. Inter-individual differences may have a genetic basis, for example associated with the
presence of concrete polymorphisms, and/or also epigenetic basis, related with a particular genotype
interaction with environmental characteristics (including diet) and life stage. Thus, interpretation of
the meaning of biomarkers may require a holistic view (Figure 1). Biomarkers may reflect the effects of
nutrient intake or a lack thereof and in certain cases, they can also act as an intermediate biomarker
that indicates the potential risk of developing a pathology associated with either excess or deficit of the
nutrient to which it is linked.
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Figure 1. Integrative nutritional biomarkers and their interest in precision nutrition. Biomarkers
of exposure include biological markers intended for the assessment of dietary food intake, whereas
biomarkers of effect/function are related to target function or biological response. These biomarkers
reflect not only the intake but also the metabolism of nutrients and, possibly, effects on disease processes.
Biomarkers of health/disease are biomarkers of ultimate goal and indicative of improved health status
and/or reduced risk of disease. Several factors (genetic, epigenetic, environment, etc.) can affect the
individual response to dietary intake and its relation to health status. There is a great interest in
the development of new types of nutritional biomarkers with an integrative trait, indicative of the
intake and effects on the organism, including its relationship with the state of health/disease and omics
technologies may play a relevant role.
To date, there is still not a clear consensus regarding the requirements for nutritional biomarkers
and the foundations needed to define optimal biomarkers for particular nutrients and their application
is a subject of extensive research [60]. In this context, it has been proposed that biomarkers should meet
the following criteria [61]: (a) they should be determined by solid, sensitive, reproducible methods,
which should be highly specific and economically feasible; (b) their concentration in the biological
sample must be sensitive enough to reflect possible changes, both in relation to the considered health
status and to the dietary intervention; (c) they must be specific to the purpose for which they are used.
It is also important that biomarkers are present in biological samples that are easily accessible and
obtained using minimally invasive techniques. Other factors, such as age, gender, ethnicity, may be of
interest depending on the purpose of use of the biomarkers.
The correct interpretation of a biomarker requires clearly defined standards of reference. Reference
values are the values of an analyte in a reference population that is usually formed by a group of
healthy individuals. If values show a normal distribution, the reference range is the population mean
±2 times the standard deviation, which is therefore the central interval of 95% of the distribution [62].
The interpretation of the results obtained in laboratory tests is based on the comparison made with said
reference values. A value which deviates from said reference range does not necessarily imply that it
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is an abnormal value but it does mean that it has a greater probability to be associated with a deficit
or excess and hence relatively closer to pathological values. Reference ranges may depend on the
characteristics of the population, age and sex; they can also vary for arterial and venous blood, specific
diets and so forth. Laboratory tests commonly used to assess nutritional status are well characterised,
although to date, there are still some nutrients for which the normal range in healthy individuals
has not been clearly defined. For example, serum 25-hydroxyvitamin D is widely recognised as a
good marker for vitamin D status, reflecting its intake and endogenous synthesis [63]. The threshold
of deficiency has been established between 25–50 nmol/L, associated with its effects on calcium and
phosphate metabolism and bone health. However, the emergence of new physiological roles of vitamin
D related to cardiovascular health seems to point to a certain benefit of higher concentrations in the
general population [64]. Moreover, serum concentrations below the reference range are not necessarily
associated with deficiency. The African-American population has, on average, lower circulating levels
compared to the Caucasian population, even though the prevalence of osteoporosis and the occurrence
of fractures are lower [65]. Thus, validated, sensitive and specific margins are required to assess the
status of various nutrients and their effects and allow for correct classification of the nutritional status.
4. Sources of Biomarkers in Nutritional Studies
The most commonly used biological samples in nutritional epidemiology are blood-borne (plasma,
serum, blood cells), excretion products (urine, faeces) or easily obtainable specimens (nails, saliva,
hair), although in certain cases it may be relevant to have biopsies or solid tissue samples (muscle,
adipose, skin).
The type of sample must be considered when processing blood samples: blood (collected with an
anticoagulant and without removing any constituent), serum (allowing blood clotting and collecting
the supernatant after subsequent centrifugation, which removes the clot and blood cells) or plasma
(the aqueous fraction containing blood proteins, electrolytes and metabolites). The assessment of
biomarkers in blood cells may also be appropriate, by analysing the respective fractions (erythrocytes
and leukocytes, mainly). For example, the determination of the omega-3 index (eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) content related to the total percentage of fatty acids) in
erythrocyte membranes is considered a good biomarker of omega-3 fatty acid intake [38].
Peripheral blood cells (PBCs) are of particular interest because they are a source of
transcriptome-based biomarkers and can be easily obtained using minimally invasive techniques.
Some of the gene expression studies in blood cells are carried out in a specific subpopulation, peripheral
blood mononuclear cells (PBMCs), including lymphocytes and monocytes, which are a reliable and
homogeneous sample for transcriptome analysis [66]. Indeed, the PBMC transcriptome reflects the
beneficial effects of a hyaluronic acid containing extract on articular health in humans [67]. Using
preclinical models, we have also shown that PBMCs can faithfully reflect effects of dietary and
environmental interventions in organs that are not accessible for analysis in healthy human subjects,
including the liver [68–70] and hypothalamus [71]. It should be noted however, that the procedure for
the isolation of PBMCs requires that a strict protocol is followed, which must be carried out immediately
after blood collection to avoid ex vivo changes in gene expression profile. This can cause a number
of logistical and technical problems, particularly when multicentre studies are involved. Existing
alternative techniques include the PAXgene blood RNA system, which allows the extraction and
stabilisation of the RNA of blood cells without additional handling [72]. This procedure offers a range
of technical advantages, such as ease in collecting, storing and transporting samples, as well as reducing
sample handling time, factors which facilitate standardisation and reproducibility. This makes it an
attractive approach for use as a source of biomarkers in human nutritional studies [73]. The limitation in
using total blood cells is that it does not allow the classification of specific cell populations. In addition,
some studies have shown increased background noise and a reduction in responsiveness to stimuli
(for example, in functional analysis) compared to the use of PBMCs [74]. However, it has been shown
that there is a significant overlap in the gene expression profile between whole blood (using PAXgene
Nutrients 2019, 11, 1092 8 of 30
tubes) and PBMCs [75] and therefore it could be expected that the identified biomarkers using PBMCs
can be extended to total blood cells, which is more attractive for large scale human studies.
For certain applications, the blood from a finger or heel prick deposited and absorbed on paper,
the so-called ‘dried blood spot’ technique, can be used for screening, for example, genetic screening of
infants for phenylketonuria or to analyse certain hormonal or metabolites, such as fatty acid analysis [76].
Due to rapid technological developments, dried blood spot approaches are currently being developed
to assess nutrient exposure [77], to identify nutrient-exposure associated risk markers [78] and to
quantify markers for nutrition-related metabolic status [79], as well as disease risk markers [80].
A recent source for blood derived biomarkers are ‘extracellular vesicles’ (EVs), which is a collective
term for cell-released, membranous structures. Recently, the International Society for Extracellular
Vesicles (ISEV) updated guidelines of Minimal Information for Studies of Extracellular Vesicles
(MISEV) to document specific EV-associated parameters, which is essential for their use as a source for
biomarkers [81]. Circulating EVs can reflect specific tissues and provide an opportunity for biomarkers
associated with tissues that are hardly accessible, such as the central nervous system [82,83]. For this
reason, EV sampling has been endowed with the term ‘liquid biopsy’ [84]. They offer the potential
for diagnosis and monitoring and, because they provide almost continuous circulating information
based on blood sampling, can potentially be used in epidemiological investigations, for example
directed at cardiovascular disease risk [85]. In fact, EV can be purified from a number of human
body fluids including plasma, saliva and breast milk, which is particularly enriched in microRNAs
(see Section 6.3.1).
Breast milk may be a source of biomarkers of the maternal nutritional and metabolic state [86,87].
A possible complicating factor is that the breast milk composition is not uniform and may be influenced
by maternal, infant and environmental factors. Hence, a sampling protocol has been proposed to
obtain an average sample [88].
Human breast milk is of particular relevance for analysis of the complex relationship between the
maternal nutritional status and infant health [89,90]. Breast milk composition may affect infant growth
and development and may have a strong impact on future metabolic health [91]. For example, animal
studies have shown that lactation by obese, diabetic or malnourished mothers predisposes for metabolic
disorders in the offspring [92]. Metabolome analysis has revealed changes in milk composition in rat
dams exposed to moderate calorie restriction during lactation, which may be associated with the lower
predisposition to obesity and the healthier phenotype described in the adult offspring [93]. However,
the possible contribution and potential benefits of specific components, as well their potential uses as
candidate biomarkers is yet to be determined.
Urine contains a concentrate of excreted metabolites and has traditionally been used to detect
metabolites or cellular material associated with renal and metabolic disorders. For example, glycosuria
indicates an abnormal use of carbohydrates and possible diabetes. The development of a metabolomic
methodology (see below) makes urine samples and blood fractions the two most relevant biological
fluids for determining nutritional biomarkers; in fact, urine is probably the most used biological source
in nutritional studies and long-term monitoring [42]. Generally, it could be stated that the metabolome
of urine reflects the food metabolome, that is, the content of ingested food, whereas blood samples reflect
changes of the endogenous metabolome, that is, the effect of such foods on the body that ingests them.
Meat intake is accompanied by high concentrations of creatine and carnitine. Creatinine is formed
by creatine biodegradation in tissue and is transported via blood to the kidneys and then excreted in
urine [25]. These metabolites have been proposed as biomarkers of meat intake, although they still
require further validation. Urine is also a fluid that may reflect the metabolism of the microbiota [25].
Thus, the intake of foods rich in polyphenols leads to the formation of hydroxyhippuric acid and other
derivatives of intestinal bacteria, which are excreted in urine [94]; similarly, urolithin A conjugates
are also identified in urine, resulting from bacterial metabolism after ingesting nuts [95]. A major
hurdle in the use of urine for biomarker analysis is the duration of the sampling period. Twenty-four
hour urine collection is considered the gold standard but is logistically challenging especially in larger
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studies. Repeated sampling in combination with modelling-based approaches may provide a solution
that will allow for shorter sampling periods [96]. Furthermore, relatively little is known about the
stability of the urine metabolome after sampling. Immediate freezing of urine samples and prevention
of freeze-thaw cycles seems to be a prerequisite for reproducible biomarker analysis [97] but is difficult
in practice, especially for 24h urine collection.
Faeces are a relevant biological source for assessing the non-absorption of nutrients [98,99],
the balance of a non-metabolizable ingredient (for example, nitrogen or trace metals that are excreted
in bile) [100], as well as to analyse the gastrointestinal microbiota or its products [101–103]. Stool
samples can also be used to assess biomarkers for enteropathy, which is attractive for infants for whom
invasive samples are difficult to obtain [104]. A growing area of study is the detection of “volatile
organic compounds” (VOCs) as a result from microbial fermentation. VOCs can be used as biomarkers
and specific VOCs were shown to be associated with the intake and type of fibre [105]. Indirect
calorimetry cages with hydrogen sensors are able to monitor microbial activity continuously and in real
time [103]. Differences in hydrogen production by highly and lowly digestible dietary carbohydrates
correspond to the abundancy of hydrogen producing bacteria [103] and to specific VOCs, including
acetic-, propionic-, butyric- and valeric acids, associated with differences in microbial activity [103].
VOCs can also be sampled from breath, which is a promising tool for diagnosis of respiratory and
other diseases [106–108]. Recently, it was also shown that analysis of VOCs in breath were different
after the intake of two different infant formulae [109]. Although the observed within and between
subject variation was high, breathomics data support that, with an appropriate study design and data
pre-processing, specific VOC profiles have been identified and associated with fat intake from dairy
drinks in comparison with a drink with the same constituents but a lower amount of fat (Hageman et
al. [110]). These studies are an initial step to the use of breathomics analysis to evaluate the metabolic
effects of nutritional interventions. The future use of compound-specific sensors and the non-invasive
nature of VOC analysis may introduce interesting analysis in newborns and infants.
Saliva is a biological fluid that is easily collected. It is used to assess adrenal functional stress and
hormone levels [111]. Furthermore, due to its minimally invasive nature, it is also one of the preferred
sources for genetic analysis, as the purified DNA extracted from saliva cells allows the detection of
specific polymorphic variants. Another accessible body fluid, less invasive and complex than serum or
plasma are tears. Tear fluid proteomic and lipidomic analyses as well as dedicated cytokine assays are
being developed to characterise ophthalmological related diseases such as dry eye disease or ocular
allergies [112–114] and identification of putative biomarkers of systemic diseases in tear fluid is being
explored [115–118].
Other easily obtainable tissues, such as nails and hair have been shown to be useful to determine
long-term excess alcohol use [119], exposure to toxic metals [120] and disease related mineral status [121],
although these specimens are usually bad indicators of body nutrient concentrations in healthy
individuals. Hair analysis can be useful in assessing concentrations of zinc, copper, chromium and
manganese for which there are no good measures of functional status [122], as well as the concentrations
of cadmium and lead that can have negative biological effects [123].
Finally, obtaining solid tissue samples of potential interest in nutritional studies, such as the liver,
to be used for, for example, gene expression analysis, proteomics or metabolomics, usually requires
invasive biopsies, which are not easily justifiable in nutritional studies in humans. Nevertheless,
adipose tissue, skeletal muscle, intestine and skin biopsies have been examined in small scale nutritional
intervention studies [124,125]. As discussed above, the use of PBMCs and EVs is particularly interesting
and may be a good alternative, especially in larger studies.
5. Types of Analysis
Two basic types of laboratory analysis are considered: static and functional. Static tests measure
the current concentration of the nutrient, bioactive or biomarker in a biological sample. Examples
of this type of analysis are the determination of serum iron, blood glucose, cholesterol and so forth.
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Circulating levels, do not necessarily reflect the amount of the substance present in body reserves
or its bioavailability. Depending on the biomarker, recent intake can influence its amount in plasma,
serum or any other fluid or tissue sample, although this limitation can be overcome, at least in part,
by collecting the sample under fasting conditions. In contrast to static analysis, functional analysis
measures a response. Although known and used for years, the pursuit of biomarkers of health has
given a boost to functional measurement of a biological function that allows for a dynamic assessment
to which a biomarker relates. Functional analysis allows for the quantification of the phenotypic
flexibility and reflects the degree of homeostatic robustness that the individual presents [55].
Functional analyses include tests, such as the oral glucose tolerance test, for assessing the
prediabetic state and insulin sensitivity and the determination of triglycerides following an oral lipid
load to assess dynamic lipidaemia as a biomarker of cardiovascular risk and early detection of metabolic
syndrome [126]. Recently, similar to fasting-refeeding challenges that are used in mice [127,128],
a standardized liquid mixed-meal with carbohydrates, fat and protein has been proposed to assess
the response of a wider set of metabolic variables in humans [129]. New type of challenges are,
for example, the response to moderate level of environmental hypoxia, oxygen restriction, to assess
age and body-weight induced metabolic alterations [130,131] and assessment of certain biomarkers in
response to fasting, which is a potential functional analysis to characterise metabolic alterations in the
obese state [132].
6. Nutrigenomic Approach in the Identification of Biomarkers
Global analysis techniques, known as “omics” have opened new research avenues in
nutrition. Advances in DNA sequencing techniques [133] and microarray technologies [134], mass
spectrometry [135] and nuclear magnetic resonance [136], among others, have facilitated simultaneous
analysis of multiple parameters and have provided unprecedented insights in responses of the
transcriptome, proteome and metabolome. The technological developments continue, especially with
regards to DNA and RNA sequencing [137], mass spectrometry [138], single-cell omics [139] and,
of course, bioinformatics [140]. Systems approaches allow obtaining a comprehensive and in-depth
view of the physiology/pathology of an individual and open the possibility to explore the complex
relationships between nutrition and health, particularly to investigate the role of dietary components
in health maintenance or in disease development [141]. For this reason, omics platforms appear to be
most suitable for the discovery and characterisation of new nutritional markers to define the nutritional
status of individuals and to identify nutritional bioactive compounds responsible for beneficial health
effects [142]. The identification of new biomarkers or patterns of biomarkers that link nutrition with
health represents one of the major challenges of omics sciences in the nutrition field.
6.1. Genetic Biomarkers
Genetic biomarkers are primarily based on the determination of genetic polymorphisms,
particularly of a single nucleotide (single nucleotide polymorphisms, SNPs). They can be determined in
DNA from any biological sample containing nucleated cells, which represents an important advantage.
Such biomarkers are static; thus, their determination does not change with time. Another feature of
these biomarkers is that samples used can be stored and transported easily, particularly once the DNA
is isolated and their determination is quick and relatively economic [53].
Polymorphic variants, which have a well-characterised biological function can be used to study
the effect of a particular environmental exposure on disease risk. There are several studies using genetic
variants as variables in environmental exposures. A well-known example is the lactase polymorphism
13910C>T (rs4988235), which is located on the MCM6 gene but influences the lactase gene (LCT). It is
strongly associated with the persistency of lactase synthesis and hence with the tolerance or intolerance
to lactose [143]. Individuals with the CC genotype usually show a physiological decline of lactase
activity in intestinal cells and have difficulty in metabolising lactose. Such individuals often exhibit
symptoms of abdominal pain and diarrhoea after consuming dairy products and therefore tend to
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consume fewer dairy products containing lactose. It has been proposed that this variant (CC genotype)
in the lactase gene may act as a proxy for low milk consumption [53,144].
The study of genetic markers has advanced considerably in recent years, thanks to, among other
things, the development of high-density arrays that allow simultaneous determination of thousands
of genetic polymorphisms. These developments have facilitated genomic wide association studies
(GWAS), which have allowed the discovery of new genes and polymorphic variants associated with
intake of specific foods, such as coffee [145] or different macronutrients [146]. Likewise, genetic variants
that affect the concentration of intake biomarkers have also been described, such as phylloquinone
(also known as vitamin K1), which is the main circulating form of vitamin K and it reflects vitamin
intake from plant [147]. Circulating phylloquinone is a biomarker of interest that has been associated
with a “healthy” lifestyle and low concentrations are associated with an increased risk of various
chronic diseases [148]. The description of gene variants that affect the concentration of phylloquinone
may explain the large inter-individual variability in the response to the intake of phylloquinone from
diet or supplements [147].
Furthermore, genetic biomarkers are crucial for determining the relationship between intermediate
biomarkers (e.g., plasma lipids, fasting glucose, oxidative markers, markers of inflammation, etc.)
and disease incidence (cardiovascular disease, type 2 diabetes, cancer, neurodegenerative diseases,
etc.). Currently there are hundreds of SNPs consistently associated with different phenotypes of
nutrition-related diseases [149,150]. Therefore, in nutritional epidemiology studies, determination
of the most relevant genetic polymorphisms associated with phenotypes of interest is important in
order to establish a reliable association between diet and disease. This is particularly relevant when
inter-individual variation has been associated with the presence of certain gene variants, which may
influence the correct assessment of nutritional status.
In addition to these considerations, genome-associated individual variability can be relevant in
the proper assessment of micronutrient status, which can have a narrow safety range between safety
and toxic doses [54,151] or modulate its bioavailability [152].
A representative example is selenium status, which is associated with an increased risk for various
chronic diseases when it is low [153]. Biological effects of selenium are largely mediated by a family of
around 25 proteins, which contain at least one selenium containing amino acid, selenocysteine [154].
Evidence suggests that individual requirements for selenium differ because of polymorphisms in
selenoprotein encoding genes. Synthesis of selenoproteins is actively regulated by the selenium
status and its expression is reduced in a hierarchical process to facilitate the expression of others
when selenium availability is limited [155]. Glutathione peroxidases (GPX), which are involved in
antioxidant function, and Selenoprotein P (SEPP), which is responsible for the selenium transport
and supply to tissues, together constitute half of the selenium in blood. Optimal selenium intake is
associated with optimal expression of all selenoproteins and when selenium is consumed above needs,
the excess is excreted, since there is no regulated reserve pool of selenium [156]. As a consequence,
genetic variation needs to be considered in assessment of selenium status. For example, individuals
with GPX1 679T/T alleles show lower plasma selenium levels than those with C/C alleles, because
this variant also accounts for differences in urinary excretion of selenium. Individuals with the
SEPP1 24731 A/A genotype show higher plasma SEPP1 levels in comparison with those with the G
allele. Gender and BMI also contribute to variation in biomarkers of selenium function [156]. Zinc
constitutes another example of an essential micronutrient, with fundamental roles in human biology,
of which the nutritional status is associated with genetic background. For example, a number of zinc
transporters coordinate zinc homeostasis. Insulin metabolism in pancreatic β-cells requires zinc and a
polymorphism in the zinc transporter SLC30A8 has been associated with increasing risk of developing
type 2 diabetes [151]. In fact, total zinc intake shows an inverse relationship with fasting plasma
glucose in individuals carrying the glucose-raising A allele. Various lines of evidence support the
concept that zinc recommendations may benefit from being personalized [151].
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6.2. Epigenetic Markers
The term epigenetics is used to describe a variety of changes in the genome that do not involve
changes in the DNA sequence but concern other chemical modifications that can result in differential
gene expression. Unlike genetic variations, which are largely fixed, epigenetic modifications are
temporal, ranging from stable within a generation to being the result of immediate adaptation to the
environment or metabolism. The main epigenetic mechanisms include DNA methylation, histone
modifications, mainly site-specific methylations and acylations [157].
DNA methylation is an epigenetic modification, which occurs in a cytosine-phosphate-guanine
dinucleotide (CpG) and involves the addition of a methyl group at the 5 position of cytosine residues
in CpG islands. This modification provides marks in the genome that establish whether the genes are
activated transcriptionally or silenced. Hypomethylation or hypermethylation of specific islands has
been associated with several disease phenotypes such as cancer, obesity or type 2 diabetes, among
others [158] or with the protection against some diseases [159]. Studies show that diet can affect the
methylation of certain DNA sites and that these changes in methylation are dynamic. For example,
CpG methylation sites have been associated with the intake of EPA and DHA from marine sources [157].
Furthermore, a diet rich in conjugated linoleic acid and calcium, which promotes weight loss in rodents,
has been associated with changes in the degree of methylation of lipid metabolism-related genes,
such as fatty acid synthase and stearoyl-CoA desaturase [160].
Epigenetic modifications caused by changes in DNA methylation status represent one of the
mechanisms that may explain the effects of metabolic programming of the offspring during the
perinatal period. For example, intrauterine growth retardation in rats was shown to block expression
of Pdx1, a pancreatic gene that mediates the glucose responsive transcription of the insulin gene,
in the offspring [161]. While this modification seems permanent in the first generation offspring,
modifications at other epigenetic marks were shown to be reversible. For example, skeletal muscle DNA
methylation of the orphan nuclear receptor Nr4a1, which is linked to insulin sensitivity, was shown
to be programmed by the mouse maternal diet and was subsequently modulated in offspring by
voluntary exercise [162]. Animal studies have also shown that changes in maternal intake during
pregnancy that affect the availability of methyl donors can alter the epigenetic pattern of certain
regions of the genome (metastable epi-alleles) in the early embryo that are stable in different tissues,
causing permanent phenotypic variation in offspring [163]. In humans, although studies are still
scarce, there is increasing evidence showing that perinatal nutrition may trigger persistent changes
in DNA methylation [164]. For example, it has been shown that variations in methyl donor intake
(associated with seasonal differences in diet: the rainy (‘hungry’) season and the dry (‘harvest’) season)
in women of a rural population of Gambia during conception predict the methylation patterns of
metastable epialleles in offspring [165,166]. Notably, 13 biomarkers, have been identified consisting in
key micronutrients involved in one-carbon metabolism, whose levels in maternal plasma may predict
DNA methylation changes at metastable epialleles in DNA from hair follicles and lymphocytes in
infants postnatally [166]. Changes in DNA methylation have also been reported in individuals with
prenatal exposure to famine, such is the case of the Dutch Hunger Winter at the end of World War
II [167,168]. Concretely, six decades later, DNA methylation levels for several loci—including insulin
like growth factor 2 (IGF2), interleukin 10 (IL10), leptin (LEP) and so forth—were found to be altered in
these individuals compared with their unexposed same-sex siblings and changes were generally found
when exposure to famine occurred during the periconceptional period, suggesting that the methylome
is more susceptible to alterations at early stages of development [167,168].
Epigenetic regulation likely involves complex interactions between various nutrients. For example,
vitamin C is an essential co-factor for multiple demethylases that regulate DNA and histones
methylation [169]. These demethylases are also sensitive to reactive oxygen species (ROS) and
tricarboxylic acid cycle (TCA) metabolites. They depend on alpha ketoglutarate and are inhibited
by succinate and fumarate. Both the electron transport chain activity, as a source of ROS and TCA
cycle are dependent on the status of various B-vitamins [170]. Vitamin C, B-vitamins and substrate
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fluxes thus interact in epigenetic regulation. Despite rapid progress, nutritional epigenetics is still in its
infancy and many more studies are needed in order to establish epigenetic markers as new biomarkers
of intake or of nutrition related health/disease.
While attention has initially been focused on DNA methylation, histone modifications are currently
emerging as nutrition-relevant epigenetic modifications. For example, methylation of histone 3 at lysine
4 of the histone tail has been associated with undernourishment in young children [171]. In particular
histone acylation, modifications by acetyl and other acyl groups, directly link epigenetically regulated
gene expression to metabolic activity, flux and status [170]. Histone acylation levels are determined
by the balance between available acylation substrates, acylase levels and activity and de-acylase
levels and activities. Acylation substrates can be provided by TCA cycle, by diet and by microbial
fermentation [172]. To illustrate further nutritional complexity, beta-oxidation as well depends on the
status of various B-vitamins [170]. Furthermore, histone deacetylase class III members, the sirtuin
family of NAD+-dependent deacylases, are dependent on vitamin B3 [173]. SIRT1 levels and histone
de-acetylase activity were also shown to be affected by supplementation with resveratrol [174,175].
6.3. Transcriptome Markers
Transcriptomics allows us to study the transcriptome, either individually for each specific gene
of interest (generally using real-time RT-PCR techniques) or for the analysis of multiple genes or
the complete set of genes expressed simultaneously in a tissue. The use of DNA-microarrays has
been established as highly robust technology for transcriptome analysis [134] but RNA sequencing
(RNA seq) is now rapidly emerging as an alternative [176]. The advantage of RNA seq over
microarrays is that a larger spectrum of RNAs is covered, which potentially can provide more
functional information [177], although in practice, most of the attention is focused on annotated
transcripts, which are also well represented on state-of-the art DNA microarrays. The use of RNA
seq requires more complex bioinformatics [178,179] and technical robustness can still be improved,
especially for small samples [180]. However, with the estimated further improvement of sequencing
technologies and associated decrease in costs, RNA seq is expected to become the future standard.
By analysing the transcriptome, we can investigate how exposure to different diets, specific foods or
components of diet, affects the expression of specific genes or more globally, the complete transcriptome.
Global transcriptome analysis has been a major tool in unravelling the molecular mechanisms of
disease and has facilitated the search and identification of biomarkers of health. The analysis of gene
expression using appropriate bioinformatics tools allows a more profound understanding of metabolic
pathways and regulatory networks and is helping to identify biomarkers for diagnosis and prognosis,
as well as potential targets for medical and nutritional intervention. Moreover, transcriptomic studies
have improved the understanding of the complex interplay between genetic and environmental factors,
such as lifestyle and nutrition factors [181,182].
The transcriptome is not the same for all cells in the body but varies depending on the tissue and
time of life, which can complicate the collection and use of such biomarkers. Moreover, as discussed
above, obtaining samples from tissues of interest, such as the liver, muscle or adipose tissue, may be a
limiting point in human studies, because it involves performing invasive biopsies. In this regard, blood
cells (PBCs), either total cells or the mononuclear cell fraction of peripheral blood (PBMCs), provide
an attractive alternative because they can be obtained relatively easily and in sufficient quantities
by minimally invasive techniques [132,183]. These cells travel throughout the body and are able
to sense and respond to internal and external signals. They have been proposed as a source of
transcriptomic biomarkers of health and disease, since their gene expression profile reflects in part the
expression profile which occurs in other tissues, particularly liver, muscle and adipose tissue, which
evolutionary derive from the same body compartment as PBMC [68–71]. Hence, changes occurring in
gene expression in such cells may be indicative of the physiological and pathological state of the body
and have a predictive component [184]. For this reason, the transcriptional profile of PBCs represents a
very useful tool for evaluating the physiological and nutritional effects of food or its components [66].
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Several studies show the association between diet and transcriptional profiling of PBCs. For
example, different gene expression profiles in PBCs in healthy individuals have been described
according to dietary patterns: a “Prudent” dietary pattern - with high intakes of fruits and vegetables
and whole grain products and low intakes of refined grain product - compared with a Western dietary
pattern [185]. Also, changes in the PBC transcriptome have been observed after consumption of diets
rich in omega-3 polyunsaturated fatty acids (omega-3 PUFAs) or other dietary modifications [66,186].
Moreover, differences in the expression of specific genes in PBCs have been described in children
related to the frequency of sugary food (TAS1R3) or high-fat (UCN2) consumption [187]. Hence,
expression levels of these genes were suggested as potential biomarkers of the frequency of intake
of specific foods, which could complement data from questionnaires [187]. Notably, in this study,
it was shown that transcript levels of TAS1R3 in PBCs were related with changes in BMI and fat-mass
after a two-year follow-up period in children, with low expression levels of this gene being related
with increased fat accumulation overtime, being a more accurately measurement than the reported
consumption of sugary foods [187]. Similarly, changes in expression levels of specific genes in PBCs
have also been described in children depending on the metabolic status and therefore they have
been proposed as potential biomarkers of risk for insulin resistance or dyslipidaemia associated with
obesity [73]. Such biomarkers, although promising, still need to be validated in other studies.
Considering the effects of certain gene variants and epigenetic modifications on the level of gene
expression, it is relevant to integrate transcriptome studies with genomics and particularly epigenomics,
since the epigenomic machinery is highly sensitive to metabolic cues [188].
6.3.1. Non-coding RNAs
Non coding RNAs (ncRNAs), both microRNAs (miRNAs) and long-chain non-coding RNAs
(lcRNAs) have emerged as regulators of mRNA transcription. For example, non-coding RNAs
have been shown to regulate a wide array of diet-induced obesity associated processes, including
adipogenesis, adipokine secretion, inflammation, glucose metabolism, lipolysis, lipogenesis, white
adipose tissue (WAT) hypoxia and WAT browning [189]. While the regulatory role of lcRNAs (>200 bp)
is still emerging [190] and is poorly investigated in the field nutrition, miRNAs have emerged as
crucial epigenetic regulators of many processes related to nutrition, including nutritional regulation of
disease related pathways [191]. MiRNAs are small RNA of 18-25 nucleotides in length, which regulate
expression of their respective target mRNAs post-transcriptionally. Dietary modulation of miRNA
expression has been shown influence various diseases, such as type 2 diabetes, obesity or hepatic
steatosis [192]. Food components have been shown to modulate the expression of miRNAs [193].
For example, diets rich in conjugated linoleic acid or PUFAs have been shown to modulate specific
miRNAs [194,195]. Some miRNAs were associated with the dietary exposure (PUFAs), while other
were associated with markers of inflammation and metabolic health [195].
MiRNAs have also been shown to enter the body from dietary sources, including plant foods and
cow milk [193] and a database has been established for the presence of miRNAs in various dietary
sources [193]. A number of studies have documented potential cross-kingdom communication by
diet/plant-derived miRNAs, although some contradictory data have also been collected and, up to
now, current controversy exists concerning the exogenous transfer and bioavailability of exogenous
miRNAs [118]. This is especially true for plant-derived miRNAs, while stronger scientific evidence
is available for cow milk miRNAs [196,197], in particular for transfer over the relatively immature
intestine of newborns. Furthermore, growing evidence indicates that miRNAs expressed in breast milk
may reflect maternal diet and nutritional status and, therefore, may influence offspring phenotype [198].
Thus, specific miRNAs have potential as biomarkers of effect, exposure and intake.
6.4. Proteomic Markers
The proteome is the set of proteins that is or can be expressed by a genome, in a cell, tissue or
organism at a certain time. As is the case with the transcriptome, the proteome is dynamic and varies
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with the cell type and its functional status. Bioactive food components usually have a limited influence
on the genome, while the effects on the transcriptome and proteome are generally greater.
Generally, readily accessible body fluids (blood, saliva or tears) contain proteins of physiological
and diagnostic importance. They are widely used in clinical tests for diagnosis and prognosis of
diseases and to follow their evolutions [199]. Tears, for example, are a complex biological fluid and
the tear proteome has been suggested as a relevant source for clinical diagnostic markers [112]. Most
human diseases involve changes in the expression of normal proteins or the creation of abnormal
proteins, that perturb physiology. In many cases, these proteins may appear in blood or other biological
fluids, thereby providing an easy access biomarker which can offer information on the disease process.
Proteomics also allows the identification of changes that occur in response to diet. For example, in an
animal model, the application of proteomic studies combined with physiological studies has provided
new insights into the mechanisms by which dietary interventions with different sources of fatty acids
(fish oil, conjugated linoleic acid and elaidic acid) regulate lipid metabolism and other related pathways
and determine changes in lipemia and insulin concentration [200].
The use of proteomic techniques for the identification of new biomarkers has generally been
limited by the characteristics of proteins and the availability of suitable techniques. The methodology
of two-dimensional electrophoresis, initially used in proteomics, has inherent disadvantages: (i) bias
towards the most abundant changes, giving a poor resolution for low abundance proteins; (ii) inability
to detect proteins with extreme properties (very small, very large, very hydrophobic or acidic or basic);
(iii) difficulty in identifying proteins, since it is time consuming and costly [201]. Recent advances in
mass spectrometry, with greater sensitivity, specificity and resolution capabilities, make it feasible to
use this technology in order to detect, identify and quantify proteins in blood and other biological
fluids. The sampling of larger number of individuals has shown that biomarker discovery with the
use of mass-spectrometry and isobaric tagging provides robust and consistent biological results [202].
Furthermore, studies also show effects of gender and phenotype, in particular age and fat mass, which
has to be taken into account for diagnostic applications [203]. A promising proteomic approach is the
protein microarray technology, which can be used to detect changes in expression and post-translational
modifications of hundreds or even thousands of proteins at the same time. Its advantages include
high sensitivity, good reproducibility, quantitative accuracy and possibility of parallel individual
determinations. These microarrays have opened new possibilities for the study of the molecular
mechanisms underlying the interactions between nutrients and genes [201]. However, it should be
noted that, compared to DNA microarrays, protein microarrays are still at an early stage of development
but its multiple applications are gradually being developed, expanded and improved. In addition
to post-translational enzymatic modification, proteins may also be modified non-enzymatically as a
consequence of metabolic fluxes. For example, advanced glycation end products (AGEs) are formed
upon reactions of sugars or sugar metabolites with proteins. Using mass spectrometry, specific AGEs
have been identified as potential biomarkers for changes in glucose metabolism related to diabetes
and/or age [204].
The use of proteomics in nutritional research has not lived up to its expectations but gradual
progress is being made. It has, for example, been examined as a tool to evaluate the effects of dietary
regimens in cancer treatment [205]. An interesting example is the use of proteomics to support the
beneficial effects of purple vegetables, carrots and potatoes on metabolic health [206]. The collection of
information on proteins and peptides, their cellular locations and functions, along with their expression
patterns in different tissues and cells, provides powerful material for defining hypotheses regarding
potential biomarkers in serum/plasma, prior to validation with specific tests [207]. The creation of
databases of proteins present in blood is expected to help identify new biomarkers [208].
6.5. Metabolomic and Lipidomic Markers
Metabolomics or metabolite profiling, can be defined as an analysis or screening of small
metabolites present in samples of biological origin [209]. Metabolomics has undergone major progress
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in the last two decades, mainly through significant innovations in instrument technology, especially
mass spectrometry and gas and liquid chromatography techniques, together with bioinformatic tools
and software [209,210]. In metabolomics, targeted and untargeted approaches can be carried out.
Targeted metabolomics allows the analysis of a defined set of known metabolites with similar structures
(e.g., amino acids, fatty acids, acylcarnitines, phytochemicals, etc.) and is generally a quantitative tool.
This approach is commonly aimed at answering specific biochemical questions or hypothesis that
motivate the investigation of one or more related pathways [210]. For example, a targeted approach
has allowed the identification of a set of five amino acids (isoleucine, leucine, valine, tyrosine and
phenylalanine) whose fasting levels strongly predicted future diabetes [211]; or a set of metabolites
(Leucine/Isoleucine and glycerol) whose response after an oral glucose tolerance test might be predictive
of insulin sensitivity [212].
Untargeted metabolomics (also referred to as “shotgun” metabolomics) consists in the unbiased
screening of metabolites in biological specimens and is generally used for global metabolite profiling
with the intention of comparing patterns of metabolites among different groups [30]. This approach is
capable to detect thousands of independent spectral features in a biological sample [209]. However,
unlike target metabolomics, only a part of the detected peaks (about one-third of them, as an estimation)
are included in databases and metabolite repositories and can be unequivocally linked to a specific
chemical structure. Untargeted metabolomic studies are generally not driven by hypothesis but are
rather hypothesis generating [210].
Metabolomics strategies, both targeted and untargeted, have clearly contributed to biomarker
discovery of the last years and many reports provide the proof-of-principle of metabolomics being a
key tool for nutrition research [30,213,214]. The comprehensive metabolite profiles (metabolome) can
provide an overview of the metabolism with a level of description that transcends genetic information
and more closely reflects the ultimate phenotype, thus helping to connect genotype to phenotype
at the molecular level [210]. If mechanistically substantiated, changes in the metabolome may be
used to improve disease risk estimates in epidemiological studies. Indeed, metabolomics is already
being successfully used in the identification of food components and their metabolites in biological
fluids [213,215]. Thus, metabolomics has allowed to define dietary exposures, for example the intake
of meat, fish, dietary pulses and so forth. [213,216–218], health status [219,220] and to examine the
result of nutritional intervention strategies [221–223].
Metabolites present in blood or other biological samples, not only reflect dietary exposure but also
metabolic processes, including the modifying effects of genetic variation and intestinal microbiota [30].
Concerning intestinal microbiota, it is of key importance to understand how changes in the microbiota
composition affect its functionality for interpretation of possible health outcomes [224]. Integrate
of serum metabolome and microbiota composition data is instrumental in linking functionality to
health [225,226]. The Mediterranean diet was, for instance, shown to modify gut microbiota with
functional consequences both in the microbiome and the host metabolome, associated with reduction
in disease risk [227]. Diet and food components can shape the composition of the gut microbiota.
For example, highly and lowly digestible fibres differentially affect gut microbiota as measured
by hydrogen production and parallel changes in hydrogen producing bacteria [228]. Not only
macronutrients, depending on their percent composition in the diet, are important for modulating
the composition of gut microbiota and their functionality [227] but also specific bioactive compounds,
such as flavonoids, whose bioconversion is highly variable dependent on the microbiome composition,
thus influencing their biological activity and the possible physiological and health outcomes [229].
Therefore, the diet modulates the microbiota but the microbiota composition also modulates the
effects of diet and food components and hence the response to diet. In this sense, the analysis of the
microbiome of the individuals may help to better interpret the response to dietary patterns/components
and has been proposed as promising for the search of biomarkers to predict individual responsiveness
to diet [227]. Thus, the use of microbiota composition as well as the integrate analysis of the metabolome
and the microbiome as biomarker of dietary assessment have biomarker discovery potential [225,226].
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Lipidomics is defined as the metabolomic analysis of lipids. It can be considered as a subfield
in metabolomics, since the different solubility properties of lipids compared to other metabolites
often determines their separate analysis [230]. Lipidomics has become the primary tool for the
identification and diagnosis of inborn errors of lipid metabolism [231]. It is now increasingly used
in nutritional studies, especial since commercial companies can deliver lipidome profiles in a robust
manner, with increasingly competitive prices. Lipidomics is being used for effect analysis [128,232]
but also to monitor dietary exposure [233,234] and the relationship between food intake and health
parameters [234,235]. Lipidomics has also been useful to provide some insights into metabolic pathways
by which food exposure may exert its health effects [235].
In recent years, metabolomics is being introduced in large cohort nutritional studies, with
promising results. The improvement of technologies, which are progressively more powerful and
sensitive and the growing availability of comprehensive databases (including food components and
their metabolic derivatives) are helping this process. For example, a metabolomic study has identified
39 known metabolites in serum which correlate with a total of 13 dietary groups, including citrus
fruits, green vegetables, red meat, shellfish, fish, peanuts, rice, butter, coffee, beer, spirits, total ethanol
and multivitamins [236]. As an example, strong associations between consumption of citrus and
stachydrine, coffee intake and trigonelline (N-methyl-nicotinate) and quinine or alcohol consumption
and ethyl glucuronide, have been described [236].
In addition to the studies carried out in serum samples, metabolomic studies have also
been done using urine samples, which have revealed the existence of markers associated with
intake, for example, with the consumption of meat (1-methylhistidine, O-acetylcarnitine) [35,41],
vegetables (phenylacetylglutamine) [41], citrus (proline betaine), oily fish (1-methylhistidine), coffee
(dyhydrocaffeic acid derivatives) [27] and tomato juice (hydroxylated and sulfonated metabolites of
esculeogenin B) [34].
In general, metabolome based biomarkers, along with others identified using the previously
described omics techniques, are of great interest in nutrition, because they can be used to monitor
intake in epidemiological or intervention studies, complementing the results of dietary questionnaires.
Moreover, the development of fast and affordable tests for relevant biomarkers of food intake could
also be of interest to routinely assess nutritional deficiencies and imbalances in the population.
7. Empowering Citizens to Monitor and Follow a Healthy Diet
The future of nutrition is moving towards the possibility of carrying out real personalised
nutrition, the emerging concept of “precision nutrition,” which may be achieved as a result of a rigorous
nutrigenomic analysis that considers the genetic makeup of the individual, its epigenetic modulation
and its molecular phenotype [59].
The health of an individual depends on the information contained in its genome and how it is
interpreted throughout its life (epigenome, methylome, transcriptome, proteome and metabolome).
The dynamic evaluation of physiology and the health status via an integrated analysis of all these
factors is what is called an integrated personal omic profile (iPOP) [237]. Although we are still far from
being able to define and use iPOPs, the first description that exists of the iPOP for a single individual
has shown the enormous potential of omics integration in medical research, in monitoring health
status and personalised medicine [237]. The iPOP is a preventive and diagnostic tool because it can
follow and to a certain extend predict, the evolution of health status and evaluate metabolic robustness.
Furthermore, it might also help to improve the assessment of disease risk and provide high diagnostic
accuracy, monitoring of disease, targeted therapies and understanding of the associated biological
processes. Clearly, the availability of such information requires powerful tools for integration and
interpretation. Hence, it is necessary to develop algorithms that enable a holistic understanding of all
the events that shape and participate in defining the health status of individuals throughout their life,
information that could be collected by conducting longitudinal iPOPS associated with crucial stages
of life.
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This concept, which would initially define the health status and the metabolic and endogenous
responses of an individual, would allow to identify certain exogenous factors, including dietary factors
that have the potential to modify the iPOP in an integrated manner, allowing to establish functional
nutritional behaviours towards improved health for the individual. The enormous development
of information technology, in terms of algorithms and appliances, can be instrumental in iPOP
implementation. The acquisition of food intake information by the consumer via mobile appliances
can be translated by image recognition software allowing for efficient identification of food ingredients.
Combining this information with a personal integrative nutritional biomarker profile, would optimally
help providing more adequate, precision nutrition recommendations. Additional physiological
information, for example to monitor glucose levels, may be provided by wearables. The use of
specifically designed platforms, for example, user-friendly mobile applications, capable of integrating
all this available information and translating it into specific outcomes, is expected to help empowering
citizens to have healthier optimal behaviours and life-style adaptations
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